Literature DB >> 10347142

Feedback regulation of beta-arrestin1 function by extracellular signal-regulated kinases.

F T Lin1, W E Miller, L M Luttrell, R J Lefkowitz.   

Abstract

The functions of beta-arrestin1 to facilitate clathrin-mediated endocytosis of the beta2-adrenergic receptor and to promote agonist-induced activation of extracellular signal-regulated kinases (ERK) are regulated by its phosphorylation/dephosphorylation at Ser-412. Cytoplasmic beta-arrestin1 is almost stoichiometrically phosphorylated at Ser-412. Dephosphorylation of beta-arrestin1 at the plasma membrane is required for targeting a signaling complex that includes the agonist-occupied receptors to the clathrin-coated pits. Here we demonstrate that beta-arrestin1 phosphorylation and function are modulated by an ERK-dependent negative feedback mechanism. ERK1 and ERK2 phosphorylate beta-arrestin1 at Ser-412 in vitro. Inhibition of ERK activity by a dominant-negative MEK1 mutant significantly attenuates beta-arrestin1 phosphorylation, thereby increasing the concentration of dephosphorylated beta-arrestin1. Under such conditions, beta-arrestin1-mediated beta2-adrenergic receptor internalization is enhanced as is its ability to bind clathrin. In contrast, if ERK-mediated phosphorylation is increased by transfection of a constitutively active MEK1 mutant, receptor internalization is inhibited. Our results suggest that dephosphorylated beta-arrestin1 mediates endocytosis-dependent ERK activation. Following activation, ERKs phosphorylate beta-arrestin1, thereby exerting an inhibitory feedback control of its function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347142     DOI: 10.1074/jbc.274.23.15971

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling.

Authors:  Sudha K Shenoy; Robert J Lefkowitz
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

2.  beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha.

Authors:  D Scott Witherow; Tiffany Runyan Garrison; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

Review 3.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

4.  Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET.

Authors:  Pascale G Charest; Sonia Terrillon; Michel Bouvier
Journal:  EMBO Rep       Date:  2005-04       Impact factor: 8.807

5.  Role of beta-arrestin 1 in the metastatic progression of colorectal cancer.

Authors:  F Gregory Buchanan; D Lee Gorden; Pranathi Matta; Qiong Shi; Lynn M Matrisian; Raymond N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 6.  Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction.

Authors:  K Defea
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 7.  Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors.

Authors:  Louis M Luttrell
Journal:  Mol Biotechnol       Date:  2008-02-01       Impact factor: 2.695

8.  S-nitrosylation of beta-arrestin regulates beta-adrenergic receptor trafficking.

Authors:  Kentaro Ozawa; Erin J Whalen; Christopher D Nelson; Yuanyu Mu; Douglas T Hess; Robert J Lefkowitz; Jonathan S Stamler
Journal:  Mol Cell       Date:  2008-08-08       Impact factor: 17.970

Review 9.  Diversity in arrestin function.

Authors:  Ryan T Kendall; Louis M Luttrell
Journal:  Cell Mol Life Sci       Date:  2009-07-12       Impact factor: 9.261

Review 10.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.